What Is MOUD? Medications for Opioid Use Disorder

Medically reviewed by Sergey Litvinov, MD — Medical Director, Pines Recovery Life. Board certified in Psychiatry and Addiction Medicine.

Medications for opioid use disorder — MOUD — are the most effective tools we have for reducing overdose risk in people recovering from opioid addiction. Three medications have FDA approval, and each works differently. Understanding the options helps patients and families make informed choices.

At a glance: MOUD includes buprenorphine (Suboxone, Subutex), methadone, and naltrexone (Vivitrol). Each medication reduces overdose risk and supports long-term recovery. The right choice depends on substance history, prior treatment, lifestyle, and medical considerations.

Buprenorphine (Suboxone / Subutex)

Buprenorphine is a partial opioid agonist — it activates opioid receptors but with a ceiling effect that significantly reduces overdose risk compared to full agonists like methadone or heroin. Suboxone combines buprenorphine with naloxone (an opioid blocker) to discourage misuse via injection; Subutex is buprenorphine alone, typically used during pregnancy or in patients sensitive to naloxone.

Buprenorphine can be prescribed in office-based settings by any physician, NP, or PA with a DEA registration. This makes it the most accessible long-term MOUD option and the most commonly used at Pines. Typical maintenance doses range from 8 to 24 mg per day, taken as sublingual films or tablets.

Methadone

Methadone is a full opioid agonist used both for pain management and for opioid use disorder. For OUD, methadone is dispensed only through licensed Opioid Treatment Programs (OTPs) — patients visit daily during early treatment, with take-home doses earned over time. The daily clinic model is restrictive but is also the most structured form of MOUD, which some patients find supportive.

Methadone has been studied longer than any other MOUD and consistently shows strong reductions in opioid use, overdose, and infectious disease transmission. It is particularly useful for patients with very high opioid tolerance, long histories of treatment failure on buprenorphine, or for those who benefit from the structure of daily clinic visits.

Naltrexone (Vivitrol)

Naltrexone is a full opioid antagonist — it blocks opioid receptors entirely. Unlike buprenorphine and methadone, naltrexone has no opioid activity itself and cannot be misused. The extended-release injectable form (Vivitrol) is given monthly and is particularly useful for patients who do not want to be on any opioid medication, including those in mandated treatment programs or specific professional contexts.

Naltrexone requires complete opioid detoxification before starting — typically 7 to 10 opioid-free days. Starting too early triggers precipitated withdrawal. This requirement makes Vivitrol best suited to patients leaving inpatient detox where the opioid-free interval can be safely managed.

Why MOUD Reduces Mortality

Multiple large studies show that MOUD reduces all-cause mortality by 50 percent or more in people with opioid use disorder, primarily by preventing overdose deaths. The risk of overdose in the first 30 days after detox without MOUD is significantly elevated because tolerance drops faster than the brain’s appetite for opioids. MOUD keeps the receptor system stable during the vulnerable early-recovery window.

The decision about whether to continue MOUD, for how long, and at what dose, is collaborative between patient and clinician. There is no universally correct duration — some patients use MOUD for months, others for years, and some indefinitely. The best outcomes correlate with longer duration of treatment, not shorter.

Frequently Asked Questions

What does MOUD stand for?

Medications for Opioid Use Disorder. The newer term replaces the older ‘medication-assisted treatment’ (MAT) because the medications are themselves the treatment, not assistive to it. The three FDA-approved MOUD options are buprenorphine, methadone, and naltrexone.

Is MOUD just trading one addiction for another?

No. This is a widespread misconception not supported by the medical evidence. MOUD stabilizes the opioid receptor system without producing the harmful patterns of substance use. Patients on stable MOUD doses can work, drive, parent, and live full lives. The research consistently shows MOUD reduces mortality, criminal activity, infectious disease transmission, and family disruption.

How long should I stay on MOUD?

There is no fixed duration. Outcomes generally improve with longer treatment. Some patients use MOUD for 6 to 12 months; others for years; others indefinitely. Discontinuation is a collaborative decision based on clinical stability, support systems, and patient preference.

Will Pines start me on MOUD during detox?

For opioid use disorder, yes. Buprenorphine induction is the standard at Pines once the patient is in mild-to-moderate withdrawal (or after a fentanyl-appropriate wash-out). Methadone requires referral to an OTP, which Pines can coordinate. Naltrexone is offered to patients who complete full opioid detoxification.

Can MOUD be used for alcohol use disorder?

Naltrexone is also FDA-approved for alcohol use disorder. Two other medications — acamprosate and disulfiram — are also used. MOUD as a term technically refers only to opioid use disorder; medications for alcohol use disorder are sometimes called MAUD.

Does insurance cover MOUD?

Most commercial plans including BCBS, UnitedHealthcare, Aetna, Cigna, Tricare, and Humana Military cover buprenorphine, methadone, and Vivitrol. Coverage details vary by plan; Pines verifies benefits at admission and throughout treatment.

Talk to someone confidentially

Insurance verification takes 60 seconds. Calls are HIPAA-protected.

Verify Insurance Call (855) 981-8935

This article is for general information and does not constitute medical advice. If you are in immediate danger, call 911. For confidential addiction treatment information, contact Pines Recovery Life at (855) 981-8935 or the SAMHSA National Helpline at 1-800-662-HELP (4357).